{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T08:18:13Z","timestamp":1793780293436,"version":"4.6.1"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"10-11","license":[{"start":{"date-parts":[[2024,9,26]],"date-time":"2024-09-26T00:00:00Z","timestamp":1727308800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,9,26]],"date-time":"2024-09-26T00:00:00Z","timestamp":1727308800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"crossref","award":["NRF-2021R1A2C1010091"],"award-info":[{"award-number":["NRF-2021R1A2C1010091"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch. Pharm. Res."],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1007\/s12272-024-01513-1","type":"journal-article","created":{"date-parts":[[2024,9,26]],"date-time":"2024-09-26T13:02:29Z","timestamp":1727355749000},"page":"812-828","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Akt-activated GSK3\u03b2 inhibitory peptide effectively blocks tau hyperphosphorylation"],"prefix":"10.1007","volume":"47","author":[{"given":"Eunjin","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujeong","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seonguk","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eun Ji","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaehoon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nam-Chul","family":"Ha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong-Gyu","family":"Jo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark P.","family":"Mattson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3203-2130","authenticated-orcid":false,"given":"Jaewon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,26]]},"reference":[{"key":"1513_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fncel.2018.00338","volume":"12","author":"AD Alonso","year":"2018","unstructured":"Alonso AD, Cohen LS, Corbo C, Morozova V, ElIdrissi A, Phillips G, Kleiman FE (2018) Hyperphosphorylation of Tau Associates with changes in its function beyond microtubule stability. Front Cell Neurosci 12:1\u201311. https:\/\/doi.org\/10.3389\/fncel.2018.00338","journal-title":"Front Cell Neurosci"},{"key":"1513_CR2","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.neuropharm.2013.07.004","volume":"76","author":"R Anand","year":"2014","unstructured":"Anand R, Gill KD, Mahdi AA (2014) Therapeutics of Alzheimer\u2019s disease: past, present and future. Neuropharmacology 76:27\u201350. https:\/\/doi.org\/10.1016\/j.neuropharm.2013.07.004","journal-title":"Neuropharmacology"},{"key":"1513_CR3","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.brainres.2004.02.081","volume":"1012","author":"GW Arendash","year":"2004","unstructured":"Arendash GW, Lewis J, Leighty RE, McGowan E, Cracchiolo JR, Hutton M, Garcia MF (2004) Multi-metric behavioral comparison of APPsw and P301L models for Alzheimer\u2019s Disease: linkage of poorer cognitive performance to tau pathology in forebrain. Brain Res 1012:29\u201341. https:\/\/doi.org\/10.1016\/j.brainres.2004.02.081","journal-title":"Brain Res"},{"key":"1513_CR4","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1074\/jbc.M112.409250","volume":"288","author":"L Avrahami","year":"2013","unstructured":"Avrahami L, Farfara D, Shaham-Kol M, Vassar R, Frenkel D, Eldar-Finkelman H (2013) Inhibition of glycogen synthase kinase-3 ameliorates \u03b2-amyloid pathology and restores lysosomal acidification and mammalian target of rapamycin activity in the Alzheimer disease mouse model: in vivo and in vitro studies. J Biol Chem 288:1295\u20131306. https:\/\/doi.org\/10.1074\/jbc.M112.409250","journal-title":"J Biol Chem"},{"key":"1513_CR5","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1159\/000358875","volume":"60","author":"A Boutajangout","year":"2014","unstructured":"Boutajangout A, Wisniewski T (2014) Tau-based therapeutic approaches for Alzheimer\u2019s disease\u2014a mini-review. Gerontology 60:381\u2013385. https:\/\/doi.org\/10.1159\/000358875","journal-title":"Gerontology"},{"key":"1513_CR6","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/s00401-010-0789-4","volume":"121","author":"H Braak","year":"2011","unstructured":"Braak H, del Tredici K (2011) The pathological process underlying Alzheimer\u2019s disease in individuals under thirty. Acta Neuropathol 121:171\u2013181. https:\/\/doi.org\/10.1007\/s00401-010-0789-4","journal-title":"Acta Neuropathol"},{"issue":"1","key":"1513_CR70","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.dadm.2014.12.001","volume":"1","author":"GA Carlesimo","year":"2015","unstructured":"Carlesimo GA, Piras F, Orfei MD, Iorio M, Caltagirone C, Spalletta G (2015) Atrophy of presubiculum and subiculum is the earliest hippocampal anatomical marker of Alzheimer\u2019s disease. Alzheimers Dement (Amst) 1(1):24\u201332. https:\/\/doi.org\/10.1016\/j.dadm.2014.12.001","journal-title":"Alzheimers Dement (Amst)"},{"key":"1513_CR7","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1007\/s00401-010-0716-8","volume":"120","author":"CM Cowan","year":"2010","unstructured":"Cowan CM, Bossing T, Page A, Shepherd D, Mudher A (2010) Soluble hyper-phosphorylated tau causes microtubule breakdown and functionally compromises normal tau in vivo. Acta Neuropathol 120:593\u2013604. https:\/\/doi.org\/10.1007\/s00401-010-0716-8","journal-title":"Acta Neuropathol"},{"key":"1513_CR8","doi-asserted-by":"publisher","first-page":"32046","DOI":"10.1074\/jbc.M201750200","volume":"277","author":"KN Dahlgren","year":"2002","unstructured":"Dahlgren KN, Manelli AM, Stine WB, Baker LK, Krafft GA, LaDu MJ (2002) Oligomeric and fibrillar species of amyloid-\u03b2 peptides differentially affect neuronal viability. J Biol Chem 277:32046\u201332053. https:\/\/doi.org\/10.1074\/jbc.M201750200","journal-title":"J Biol Chem"},{"key":"1513_CR9","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1038\/sj.mp.4001208","volume":"8","author":"GV De Ferrari","year":"2003","unstructured":"De Ferrari GV, Chacon MA, Barria MI, Garrido JL, Godoy JA, Olivares G, Reyes AE, Alvarez A, Bronfman M, Inestrosa NC (2003) Activation of Wnt signaling rescues neurodegeneration and behavioral impairments induced by \u03b2-amyloid fibrils. Mol Psychiatr 8:195\u2013208. https:\/\/doi.org\/10.1038\/sj.mp.4001208","journal-title":"Mol Psychiatr"},{"key":"1513_CR10","doi-asserted-by":"publisher","first-page":"205","DOI":"10.3233\/JAD-2012-120805","volume":"33","author":"T Del Ser","year":"2013","unstructured":"Del Ser T, Steinwachs KC, Gertz HJ, Andres MV, Gomez-Carrillo B, Medina M, Vericat JA, Redondo P, Fleet D, Leon T (2013) Treatment of Alzheimer\u2019s disease with the GSK-3 inhibitor tideglusib: a pilot study. J Alzheimer\u2019s Dis 33:205\u2013215. https:\/\/doi.org\/10.3233\/JAD-2012-120805","journal-title":"J Alzheimer\u2019s Dis"},{"key":"1513_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.neurobiolaging.2007.05.010","volume":"30","author":"F Denk","year":"2009","unstructured":"Denk F, Wade-Martins R (2009) Knock-out and transgenic mouse models of tauopathies. Neurobiol Aging 30:1\u201313. https:\/\/doi.org\/10.1016\/j.neurobiolaging.2007.05.010","journal-title":"Neurobiol Aging"},{"key":"1513_CR12","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1002\/glia.20734","volume":"57","author":"MK Desai","year":"2009","unstructured":"Desai MK, Sudol KL, Janelsins MC, Mastrangelo MA, Frazer ME, Bowers WJ (2009) Triple-transgenic Alzheimer\u2019s disease mice exhibit region-specific abnormalities in brain myelination patterns prior to appearance of amyloid and tau pathology. Glia 57:54\u201365. https:\/\/doi.org\/10.1002\/glia.20734","journal-title":"Glia"},{"key":"1513_CR13","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.nbd.2010.03.022","volume":"39","author":"Y Ding","year":"2010","unstructured":"Ding Y, Qiao A, Fan GH (2010) Indirubin-3\u2019-monoxime rescues spatial memory deficits and attenuates \u03b2-amyloid-associated neuropathology in a mouse model of Alzheimer\u2019s disease. Neurobiol Dis 39:156\u2013168. https:\/\/doi.org\/10.1016\/j.nbd.2010.03.022","journal-title":"Neurobiol Dis"},{"key":"1513_CR14","doi-asserted-by":"publisher","first-page":"675","DOI":"10.3109\/1061186X.2010.531729","volume":"19","author":"L Fei","year":"2011","unstructured":"Fei L, Ren L, Zaro JL, Shen WC (2011) The influence of net charge and charge distribution on cellular uptake and cytosolic localization of arginine-rich peptides. J Drug Target 19:675\u2013680. https:\/\/doi.org\/10.3109\/1061186X.2010.531729","journal-title":"J Drug Target"},{"key":"1513_CR15","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1192\/bjp.2019.76","volume":"215","author":"OV Forlenza","year":"2019","unstructured":"Forlenza OV, Radanovic M, Talib LL, Gattaz WF (2019) Clinical and biological effects of long-term lithium treatment in older adults with amnestic mild cognitive impairment: Randomised clinical trial. Br J Psychiatr 215:668\u2013674. https:\/\/doi.org\/10.1192\/bjp.2019.76","journal-title":"Br J Psychiatr"},{"key":"1513_CR16","doi-asserted-by":"publisher","first-page":"18041","DOI":"10.1073\/pnas.0907652106","volume":"106","author":"K Ghosal","year":"2009","unstructured":"Ghosal K, Vogt DL, Liang M, Shen Y, Lamb BT, Pimplikar SW (2009) Alzheimer\u2019s disease-like pathological features in transgenic mice expressing the APP intracellular domain. Proc the Natl Acad of Sci 106:18041\u201318042","journal-title":"Proc the Natl Acad of Sci"},{"key":"1513_CR17","doi-asserted-by":"publisher","first-page":"2321","DOI":"10.2174\/092986708785909111","volume":"15","author":"C-X Gong","year":"2008","unstructured":"Gong C-X, Iqbal K (2008) Hyperphosphorylation of microtubule-associated protein tau: a promising therapeutic target for Alzheimer disease. Curr Med Chem 15:2321\u20132328. https:\/\/doi.org\/10.2174\/092986708785909111","journal-title":"Curr Med Chem"},{"key":"1513_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-019-54557-5","volume":"9","author":"G Griebel","year":"2019","unstructured":"Griebel G, Stemmelin J, Lopez-Grancha M, Boulay D, Boquet G, Slowinski F, Pichat P, Beesk\u00e9 S, Tanaka S, Mori A, Fujimura M (2019) The selective GSK3 inhibitor, SAR502250, displays neuroprotective activity and attenuates behavioral impairments in models of neuropsychiatric symptoms of Alzheimer\u2019s disease in rodents. Sci Rep 9:1\u201315. https:\/\/doi.org\/10.1038\/s41598-019-54557-5","journal-title":"Sci Rep"},{"key":"1513_CR19","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.08m04606","author":"H Hampel","year":"2009","unstructured":"Hampel H, Ewers M, Burger K, Annas P, Mortberg A, Bogstedt A, Frolich L, Schroder J, Schonknecht P, Riepe MW, Kraft I (2009) Lithium trial in Alzheimer\u2019s disease: a randomized, single-blind, placebo-controlled, multicenter 10-week study. J Clin Psychiatr. https:\/\/doi.org\/10.4088\/JCP.08m04606","journal-title":"J Clin Psychiatr"},{"key":"1513_CR20","doi-asserted-by":"publisher","first-page":"271","DOI":"10.2174\/1567202611666140520151002","volume":"11","author":"P Hanumanthappa","year":"2014","unstructured":"Hanumanthappa P, Densi A, Krishnamurthy R (2014) Glycogen synthase kinase-3 in ischemic neuronal death. Curr Neurovasc Res 11:271\u2013278. https:\/\/doi.org\/10.2174\/1567202611666140520151002","journal-title":"Curr Neurovasc Res"},{"key":"1513_CR21","doi-asserted-by":"publisher","first-page":"2373","DOI":"10.3892\/or.2020.7817","volume":"44","author":"R He","year":"2020","unstructured":"He R, Du S, Lei T, Xie X, Wang Y (2020) Glycogen synthase kinase 3\u03b2 in tumorigenesis and oncotherapy (Review). Oncol Rep 44:2373\u20132385. https:\/\/doi.org\/10.3892\/or.2020.7817","journal-title":"Oncol Rep"},{"key":"1513_CR121","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1002\/hipo.20759","volume":"21","author":"RA Hill","year":"2011","unstructured":"Hill RA, Murray SS, Halley PG, Binder MD, Martin SJ, van den Buuse M (2011) Brain-derived neurotrophic factor expression is increased in the hippocampus of 5-HT2C receptor knockout mice. Hippocampus 21:434\u2013445. https:\/\/doi.org\/10.1002\/hipo.20759","journal-title":"Hippocampus"},{"key":"1513_CR22","doi-asserted-by":"publisher","DOI":"10.3390\/cells9040820","author":"L Hoffmeister","year":"2020","unstructured":"Hoffmeister L, Diekmann M, Brand K, Huber R (2020) GSK3: a kinase balancing promotion and resolution of inflammation. Cells. https:\/\/doi.org\/10.3390\/cells9040820","journal-title":"Cells"},{"key":"1513_CR23","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1038\/nn.2785","volume":"14","author":"J Jo","year":"2011","unstructured":"Jo J, Whitcomb DJ, Olsen KM, Kerrigan TL, Lo SC, Bru-Mercier G, Dickinson B, Scullion S, Sheng M, Collingridge G, Cho K (2011) A\u03b21-42 inhibition of LTP is mediated by a signaling pathway involving caspase-3, Akt1 and GSK-3\u03b2. Nat Neurosci 14:545\u2013547. https:\/\/doi.org\/10.1038\/nn.2785","journal-title":"Nat Neurosci"},{"key":"1513_CR24","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/S0165-6147(03)00206-2","volume":"24","author":"RS Jope","year":"2003","unstructured":"Jope RS (2003) Lithium and GSK-3: one inhibitor, two inhibitory actions, multiple outcomes. Trends Pharmacol Sci 24:441\u2013443. https:\/\/doi.org\/10.1016\/S0165-6147(03)00206-2","journal-title":"Trends Pharmacol Sci"},{"key":"1513_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fnmol.2011.00016","volume":"4","author":"RS Jope","year":"2011","unstructured":"Jope RS (2011) Glycogen synthase kinase-3 in the etiology and treatment of mood disorders. Front Mol Neurosci 4:1\u201311. https:\/\/doi.org\/10.3389\/fnmol.2011.00016","journal-title":"Front Mol Neurosci"},{"key":"1513_CR26","doi-asserted-by":"publisher","first-page":"106349","DOI":"10.1016\/j.jstrokecerebrovasdis.2022.106349","volume":"31","author":"B Joshi","year":"2022","unstructured":"Joshi B, Singh D, Wasan H, Sharma U, Reeta KH (2022a) Tideglusib ameliorates ischemia\/reperfusion damage by inhibiting GSK-3\u03b2 and apoptosis in rat model of ischemic stroke. J Stroke Cerebrovasc Dis 31:106349. https:\/\/doi.org\/10.1016\/j.jstrokecerebrovasdis.2022.106349","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"1513_CR27","doi-asserted-by":"publisher","unstructured":"Joshi D, Gupta G, Narayan G, Mishra VN, Chaurasia R, Pathak A, Singh VK and Kumar A (2022b) GSK-3\u03b2 inhibitors can rescue neurons through the prosurvival (autophagy) mechanism in Parkinson\u2019s disease. https:\/\/doi.org\/10.21203\/rs.3.rs-1533307\/v1","DOI":"10.21203\/rs.3.rs-1533307\/v1"},{"key":"1513_CR28","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/j.bbrc.2013.03.103","volume":"434","author":"JS Kim","year":"2013","unstructured":"Kim JS, Piao S, Lee E, Yoon BY, Moon HR, Lee J, Jung Y, Ha NC (2013) Development of Akt-activated GSK3\u03b2 inhibitory peptide. Biochem Biophys Res Commun 434:735\u2013739. https:\/\/doi.org\/10.1016\/j.bbrc.2013.03.103","journal-title":"Biochem Biophys Res Commun"},{"key":"1513_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/alzrt265","volume":"6","author":"Y Kitagishi","year":"2014","unstructured":"Kitagishi Y, Nakanishi A, Ogura Y, Matsuda S (2014) Dietary regulation of PI3K\/AKT\/GSK-3 \u03b2 pathway in Alzheimer \u2018 s disease. Alzheimers Res Ther 6:1\u20137. https:\/\/doi.org\/10.1186\/alzrt265","journal-title":"Alzheimers Res Ther"},{"key":"1513_CR30","doi-asserted-by":"publisher","first-page":"8455","DOI":"10.1073\/pnas.93.16.8455","volume":"93","author":"PS Klein","year":"1996","unstructured":"Klein PS, Melton DA (1996) A molecular mechanism for the effect of lithium on development. Proc Natl Acad Sci USA 93:8455\u20138459. https:\/\/doi.org\/10.1073\/pnas.93.16.8455","journal-title":"Proc Natl Acad Sci USA"},{"key":"1513_CR31","doi-asserted-by":"publisher","first-page":"118664","DOI":"10.1016\/j.bbamcr.2020.118664","volume":"1867","author":"E Lauretti","year":"2020","unstructured":"Lauretti E, Dincer O, Pratic\u00f2 D (2020) Glycogen synthase kinase-3 signaling in Alzheimer\u2019s disease. Biochim Biophys Acta Mol Cell Res 1867:118664. https:\/\/doi.org\/10.1016\/j.bbamcr.2020.118664","journal-title":"Biochim Biophys Acta Mol Cell Res"},{"key":"1513_CR32","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.3892\/etm.2014.1858","volume":"8","author":"X Li","year":"2014","unstructured":"Li X, Zhang J, Chai S, Wang X (2014) Progesterone alleviates hypoxic-ischemic brain injury via the Akt\/GSK-3\u03b2 signaling pathway. Exp Ther Med 8:1241\u20131246. https:\/\/doi.org\/10.3892\/etm.2014.1858","journal-title":"Exp Ther Med"},{"key":"1513_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijms21124215","volume":"21","author":"CI Lin","year":"2020","unstructured":"Lin CI, Chang YC, Kao NJ, Lee WJ, Cross TW, Lin SH (2020) 1,25(OH)2D3 alleviates a\u03b2(25\u201335)-induced tau hyperphosphorylation, excessive reactive oxygen species, and apoptosis through interplay with glial cell line-derived neurotrophic factor signaling in SH-SY5Y cells. Int J Mol Sci 21:1\u201317. https:\/\/doi.org\/10.3390\/ijms21124215","journal-title":"Int J Mol Sci"},{"key":"1513_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fnmol.2014.00046","volume":"7","author":"M Llorens-Mart\u00edn","year":"2014","unstructured":"Llorens-Mart\u00edn M, Jurado J, Hern\u00e1ndez F, \u00c1vila J (2014) GSK-3\u03b2, a pivotal kinase in Alzheimer disease. Front Mol Neurosci 7:1\u201311. https:\/\/doi.org\/10.3389\/fnmol.2014.00046","journal-title":"Front Mol Neurosci"},{"key":"1513_CR35","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1602\/neurorx.1.1.117","volume":"1","author":"FM Longo","year":"2004","unstructured":"Longo FM, Massa SM (2004) Neuroprotective strategies in Alzheimer\u2019s disease. NeuroRx 1:117\u2013127. https:\/\/doi.org\/10.1602\/neurorx.1.1.117","journal-title":"NeuroRx"},{"key":"1513_CR36","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.14336\/AD.2018.0201","volume":"9","author":"A Luca","year":"2018","unstructured":"Luca A, Calandra C, Luca M (2018) Molecular bases of Alzheimer\u2019s disease and neurodegeneration: the role of neuroglia. Aging Dis 9:1134\u20131152. https:\/\/doi.org\/10.14336\/AD.2018.0201","journal-title":"Aging Dis"},{"key":"1513_CR37","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1093\/emboj\/20.1.27","volume":"20","author":"JJ Lucas","year":"2001","unstructured":"Lucas JJ, Hern\u00e1ndez F, G\u00f3mez-Ramos P, Mor\u00e1n MA, Hen R, Avila J (2001) Decreased nuclear \u03b2-catenin, tau hyperphosphorylation and neurodegeneration in GSK-3\u03b2 conditional transgenic mice. EMBO J 20:27\u201339. https:\/\/doi.org\/10.1093\/emboj\/20.1.27","journal-title":"EMBO J"},{"key":"1513_CR38","doi-asserted-by":"publisher","first-page":"4332","DOI":"10.2174\/1381612823666170714141450","volume":"23","author":"M Maqbool","year":"2017","unstructured":"Maqbool M, Hoda N (2017) GSK3 inhibitors in the therapeutic development of diabetes, cancer and neurodegeneration: past, present and future. Curr Pharm Des 23:4332\u20134350. https:\/\/doi.org\/10.2174\/1381612823666170714141450","journal-title":"Curr Pharm Des"},{"key":"1513_CR39","doi-asserted-by":"publisher","first-page":"2881","DOI":"10.18632\/oncotarget.2037","volume":"5","author":"JA McCubrey","year":"2014","unstructured":"McCubrey JA, Steelman LS, Bertrand FE, Davis NM, Sokolosky M, Abrams SL, Montalto G, D\u2019Assoro AB, Libra M, Nicoletti F, Maestro R (2014) GSK-3 as potential target for therapeutic irvention in cancer. Oncotarget 5:2881\u20132911. https:\/\/doi.org\/10.18632\/oncotarget.2037","journal-title":"Oncotarget"},{"key":"1513_CR40","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.1038\/s41386-020-00819-0","volume":"45","author":"K Nakao","year":"2020","unstructured":"Nakao K, Singh M, Sapkota K, Hagler BC, Hunter RN, Raman C, Hablitz JJ, Nakazawa K (2020) GSK3\u03b2 inhibition restores cortical gamma oscillation and cognitive behavior in a mouse model of NMDA receptor hypofunction relevant to schizophrenia. Neuropsychopharmacology 45:2207\u20132218. https:\/\/doi.org\/10.1038\/s41386-020-00819-0","journal-title":"Neuropsychopharmacology"},{"key":"1513_CR41","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1038\/nrn1385","volume":"5","author":"K Nakazawa","year":"2004","unstructured":"Nakazawa K, McHugh TJ, Wilson MA, Tonegawa S (2004) NMDA receptors, place cells and hippocampal spatial memory. Nat Rev Neurosci 5:361\u2013372. https:\/\/doi.org\/10.1038\/nrn1385","journal-title":"Nat Rev Neurosci"},{"key":"1513_CR42","doi-asserted-by":"publisher","first-page":"6990","DOI":"10.1073\/pnas.0500466102","volume":"102","author":"W Noble","year":"2005","unstructured":"Noble W, Planel E, Zehr C, Olm V, Meyerson J, Suleman F, Gaynor K, Wang L, LaFrancois J, Feinstein B, Burns M (2005) Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo. Proc Natl Acad Sci U S A 102:6990\u20136995. https:\/\/doi.org\/10.1073\/pnas.0500466102","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1513_CR43","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.lfs.2016.06.020","volume":"158","author":"A Noel","year":"2016","unstructured":"Noel A, Barrier L, Ingrand S (2016) The Tyr216 phosphorylated form of GSK3\u03b2 contributes to tau phosphorylation at PHF-1 epitope in response to A\u03b2 in the nucleus of SH-SY5Y cells. Life Sci 158:14\u201321. https:\/\/doi.org\/10.1016\/j.lfs.2016.06.020","journal-title":"Life Sci"},{"key":"1513_CR44","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/S0896-6273(03)00434-3","volume":"39","author":"S Oddo","year":"2003","unstructured":"Oddo S, Caccamo A, Shepherd JD, Murphy MP, Golde TE, Kayed R, Metherate R, Mattson MP, Akbari Y, LaFerla FM (2003) Triple-transgenic model of Alzheimer\u2019s disease with plaques and tangles: intracellular A\u03b2 and synaptic dysfunction. Neuron 39:409\u2013421. https:\/\/doi.org\/10.1016\/S0896-6273(03)00434-3","journal-title":"Neuron"},{"key":"1513_CR45","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1111\/j.1471-4159.2011.07532.x","volume":"119","author":"T Onishi","year":"2011","unstructured":"Onishi T, Iwashita H, Uno Y, Kunitomo J, Saitoh M, Kimura E, Fujita H, Uchiyama N, Kori M, Takizawa M (2011) A novel glycogen synthase kinase-3 inhibitor 2-methyl-5-(3-{4-[(S)- methylsulfinyl]phenyl}-1-benzofuran-5-yl)-1,3,4-oxadiazole decreases tau phosphorylation and ameliorates cognitive deficits in a transgenic model of Alzheimer\u2019s disease. J Neurochem 119:1330\u20131340. https:\/\/doi.org\/10.1111\/j.1471-4159.2011.07532.x","journal-title":"J Neurochem"},{"key":"1513_CR46","doi-asserted-by":"publisher","first-page":"301","DOI":"10.3233\/JAD-2003-5405","volume":"5","author":"M P\u00e9rez","year":"2003","unstructured":"P\u00e9rez M, Hern\u00e1ndez F, Lim F, D\u00edaz-Nido J, Avila J (2003) Chronic lithium treatment decreases mutant tau protein aggregation in a transgenic mouse model. J Alzheimer\u2019s Dis 5:301\u2013308. https:\/\/doi.org\/10.3233\/JAD-2003-5405","journal-title":"J Alzheimer\u2019s Dis"},{"key":"1513_CR47","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1007\/s00401-013-1215-5","volume":"127","author":"M Polydoro","year":"2014","unstructured":"Polydoro M, Dzhala VI, Pooler AM, Nicholls SB, McKinney AP, Sanchez L, Pitstick R, Carlson GA, Staley KJ, Spires-Jones TL, Hyman BT (2014) Soluble pathological tau in the entorhinal cortex leads to presynaptic deficits in an early Alzheimer\u2019s disease model. Acta Neuropathol 127:257\u2013270. https:\/\/doi.org\/10.1007\/s00401-013-1215-5","journal-title":"Acta Neuropathol"},{"key":"1513_CR48","doi-asserted-by":"publisher","first-page":"10637","DOI":"10.1523\/JNEUROSCI.3279-05.2005","volume":"25","author":"M Ramsden","year":"2005","unstructured":"Ramsden M, Kotilinek L, Forster C, Paulson J, McGowan E, SantaCruz K, Guimaraes A, Yue M, Lewis J, Carlson G, Hutton M (2005) Age-dependent neurofibrillary tangle formation, neuron loss, and memory impairment in a mouse model of human tauopathy (P301L). J Neurosci 25:10637\u201310647. https:\/\/doi.org\/10.1523\/JNEUROSCI.3279-05.2005","journal-title":"J Neurosci"},{"key":"1513_CR49","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cells10020262","volume":"10","author":"I Rippin","year":"2021","unstructured":"Rippin I, Eldar-Finkelman H (2021) Mechanisms and therapeutic implications of gsk-3 in treating neurodegeneration. Cells 10:1\u201322. https:\/\/doi.org\/10.3390\/cells10020262","journal-title":"Cells"},{"key":"1513_CR50","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1523\/JNEUROSCI.4321-06.2007","volume":"27","author":"E Rockenstein","year":"2007","unstructured":"Rockenstein E, Torrance M, Adame A, Mante M, Bar-On P, Rose JB, Crews L, Masliah E (2007) Neuroprotective effects of regulators of the glycogen synthase kinase-3\u03b2 signaling pathway in a transgenic model of Alzheimer\u2019s disease are associated with reduced amyloid precursor protein phosphorylation. J Neurosci 27:1981\u20131991. https:\/\/doi.org\/10.1523\/JNEUROSCI.4321-06.2007","journal-title":"J Neurosci"},{"key":"1513_CR51","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/S0736-5748(02)00047-3","volume":"20","author":"EE Rodgers","year":"2002","unstructured":"Rodgers EE, Theibert AB (2002) Functions of PI 3-kinase in development of the nervous system. Int J Dev Neurosci 20:187\u2013197. https:\/\/doi.org\/10.1016\/S0736-5748(02)00047-3","journal-title":"Int J Dev Neurosci"},{"key":"1513_CR52","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cells10020255","volume":"10","author":"ME Snitow","year":"2021","unstructured":"Snitow ME, Bhansali RS, Klein PS (2021) Lithium and therapeutic targeting of gsk-3. Cells 10:1\u201324. https:\/\/doi.org\/10.3390\/cells10020255","journal-title":"Cells"},{"key":"1513_CR53","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/S0306-4522(02)00236-1","volume":"113","author":"K Spittaels","year":"2002","unstructured":"Spittaels K, Van den Haute C, Van Dorpe J, Terwel D, Vandezande K, Lasrado R, Bruynseels K, Irizarry M, Verhoye M, Van Lint J, Vandenheede JR (2002) Neonatal neuronal overexpression of glycogen synthase kinase-3\u03b2 reduces brain size in transgenic mice. Neuroscience 113:797\u2013808. https:\/\/doi.org\/10.1016\/S0306-4522(02)00236-1","journal-title":"Neuroscience"},{"key":"1513_CR54","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/0166-4328(90)90072-M","volume":"37","author":"RJ Sutherland","year":"1990","unstructured":"Sutherland RJ, McDonald RJ (1990) Hippocampus, amygdala, and memory deficits in rats. Behav Brain Res 37:57\u201379. https:\/\/doi.org\/10.1016\/0166-4328(90)90072-M","journal-title":"Behav Brain Res"},{"key":"1513_CR55","doi-asserted-by":"publisher","first-page":"2511","DOI":"10.1523\/JNEUROSCI.5245-10.2011","volume":"31","author":"A Sydow","year":"2011","unstructured":"Sydow A, van der Jeugd A, Zheng F et al (2011) Tau-induced defects in synaptic plasticity, learning, and memory are reversible in transgenic mice after switching off the toxic tau mutant. J Neurosci 31:2511\u20132525. https:\/\/doi.org\/10.1523\/JNEUROSCI.5245-10.2011","journal-title":"J Neurosci"},{"key":"1513_CR56","first-page":"158","volume":"1","author":"P Taupin","year":"2010","unstructured":"Taupin P (2010) Aging and neurogenesis, a lesion from Alzheimer\u2019s disease. Aging Dis 1:158\u2013168","journal-title":"Aging Dis"},{"key":"1513_CR57","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fncel.2013.00189","volume":"6","author":"V Tell","year":"2013","unstructured":"Tell V, Hilgeroth A (2013) Recent developments of protein kinase inhibitors as potential AD therapeutics. Front Cell Neurosci 6:1\u20138. https:\/\/doi.org\/10.3389\/fncel.2013.00189","journal-title":"Front Cell Neurosci"},{"key":"1513_CR58","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1038\/mp.2009.72","volume":"15","author":"EM Toledo","year":"2010","unstructured":"Toledo EM, Inestrosa NC (2010) Activation of Wnt signaling by lithium and rosiglitazone reduced spatial memory impairment and neurodegeneration in brains of an APPswe\/PSEN1\u0394E9 mouse model of Alzheimer\u2019s disease. Mol Psychiatr 15:272\u2013285. https:\/\/doi.org\/10.1038\/mp.2009.72","journal-title":"Mol Psychiatr"},{"key":"1513_CR59","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1161\/STROKEAHA.111.646224","volume":"43","author":"Y Ueno","year":"2012","unstructured":"Ueno Y, Chopp M, Zhang L, Buller B, Liu Z, Lehman NL, Liu XS, Zhang Y, Roberts C, Zhang ZG (2012) Axonal outgrowth and dendritic plasticity in the cortical peri-infarct area after experimental stroke. Stroke 43:2221\u20132228. https:\/\/doi.org\/10.1161\/STROKEAHA.111.646224","journal-title":"Stroke"},{"key":"1513_CR60","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1007\/s00401-012-0987-3","volume":"123","author":"A Van der Jeugd","year":"2012","unstructured":"Van der Jeugd A, Hochgr\u00e4fe K, Ahmed T, Decker JM, Sydow A, Hofmann A, Wu D, Messing L, Balschun D, D\u2019Hooge R, Mandelkow EM (2012) Cognitive defects are reversible in inducible mice expressing pro-aggregant full-length human Tau. Acta Neuropathol 123:787\u2013805. https:\/\/doi.org\/10.1007\/s00401-012-0987-3","journal-title":"Acta Neuropathol"},{"key":"1513_CR61","doi-asserted-by":"publisher","first-page":"49676","DOI":"10.1074\/jbc.M208756200","volume":"277","author":"CE Wrede","year":"2002","unstructured":"Wrede CE, Dickson LM, Lingohr MK, Briaud I, Rhodes CJ (2002) Protein kinase B\/Akt prevents fatty acid-induced apoptosis in pancreatic \u03b2-cells (INS-1). J Biol Chem 277:49676\u201349684. https:\/\/doi.org\/10.1074\/jbc.M208756200","journal-title":"J Biol Chem"},{"key":"1513_CR62","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.bbrc.2014.10.025","volume":"454","author":"L Xu","year":"2014","unstructured":"Xu L, Li Y, Fu Q, Ma S (2014) Perillaldehyde attenuates cerebral ischemia-reperfusion injury-triggered overexpression of inflammatory cytokines via modulating Akt\/JNK pathway in the rat brain cortex. Biochem Biophys Res Commun 454:65\u201370. https:\/\/doi.org\/10.1016\/j.bbrc.2014.10.025","journal-title":"Biochem Biophys Res Commun"},{"key":"1513_CR63","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/S0891-0618(02)00014-5","volume":"23","author":"HB Yao","year":"2002","unstructured":"Yao HB, Shaw PC, Wong CC, Wan DCC (2002) Expression of glycogen synthase kinase-3 isoforms in mouse tissues and their transcription in the brain. J Chem Neuroanat 23:291\u2013297. https:\/\/doi.org\/10.1016\/S0891-0618(02)00014-5","journal-title":"J Chem Neuroanat"},{"key":"1513_CR64","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.bbrc.2009.02.044","volume":"381","author":"S Yum","year":"2009","unstructured":"Yum S, Lee SJ, Piao S, Xu Y, Jung J, Jung Y, Oh S, Lee J, Park BJ, Ha NC (2009) The role of the Ser\/Thr cluster in the phosphorylation of PPPSP motifs in Wnt coreceptors. Biochem Biophys Res Commun 381:345\u2013349. https:\/\/doi.org\/10.1016\/j.bbrc.2009.02.044","journal-title":"Biochem Biophys Res Commun"}],"container-title":["Archives of Pharmacal Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12272-024-01513-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12272-024-01513-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12272-024-01513-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,28]],"date-time":"2024-11-28T08:30:55Z","timestamp":1732782655000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12272-024-01513-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,26]]},"references-count":66,"journal-issue":{"issue":"10-11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["1513"],"URL":"https:\/\/doi.org\/10.1007\/s12272-024-01513-1","relation":{},"ISSN":["0253-6269","1976-3786"],"issn-type":[{"value":"0253-6269","type":"print"},{"value":"1976-3786","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,26]]},"assertion":[{"value":"13 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declared no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}